When Was Ozempic Approved by the FDA? Complete Timeline From 2017 to 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide injection) received FDA approval on December 5, 2017, for type 2 diabetes management in adults
• The cardiovascular risk reduction indication was added in January 2020 based on the SUSTAIN-6 trial showing 26% reduction in major adverse cardiovascular events
• The 2 mg dose was approved in January 2022, doubling the maximum available dose from the original 1 mg limit
• As of 2026, Ozempic remains approved only for type 2 diabetes, not weight loss (that indication belongs to Wegovy, approved June 2021)

Direct answer (40-60 words)

Ozempic was approved by the FDA on December 5, 2017, as a once-weekly injectable treatment for type 2 diabetes in adults. The initial approval covered 0.5 mg and 1 mg doses. Novo Nordisk submitted the New Drug Application (NDA) in December 2016, receiving priority review status due to semaglutide's superior A1C reduction compared to existing GLP-1 therapies.

Table of contents

1. The December 2017 approval: what the FDA actually approved
2. The clinical trial evidence that secured approval
3. Timeline of label expansions (2017 to 2026)
4. What most articles get wrong about Ozempic's approval
5. The cardiovascular indication: how SUSTAIN-6 changed the label
6. The 2 mg dose approval and why it took until 2022
7. Ozempic vs Wegovy: why two approval dates for the same molecule
8. The 2023-2026 shortage and FDA regulatory response
9. Current approved indications as of April 2026
10. How approval dates affect insurance coverage and compounding legality
11. What's next: pending label changes and post-market studies
12. FAQ

The December 2017 approval: what the FDA actually approved

The FDA approved Ozempic (semaglutide injection) on December 5, 2017, under NDA 209637. The approval letter specified three elements:

Approved indication: "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

Approved doses: 0.5 mg once weekly and 1 mg once weekly, administered subcutaneously. The approval included a starting dose of 0.25 mg once weekly for four weeks (not a therapeutic dose, but a tolerability step).

Approved delivery system: pre-filled, multi-dose pen delivering doses via a disposable needle. Each pen contained 2 mg semaglutide in 1.5 mL solution (concentration: 1.34 mg/mL).

The approval did not include weight loss, obesity management, or use in patients without type 2 diabetes. The FDA's approval letter explicitly stated the indication was limited to glycemic control, not weight reduction, even though the SUSTAIN trials documented substantial weight loss as a secondary outcome.

Novo Nordisk submitted the NDA on December 21, 2016. The FDA granted priority review in February 2017, shortening the standard 10-month review to six months. Priority review is reserved for drugs that demonstrate significant improvement over existing treatments. Semaglutide's A1C reduction of 1.5% to 1.8% in the SUSTAIN trials exceeded the 0.8% to 1.2% typical of earlier GLP-1 receptor agonists like liraglutide (Victoza) and dulaglutide (Trujicity).

The clinical trial evidence that secured approval

The FDA based its approval on the SUSTAIN clinical trial program, a series of eight Phase 3 trials enrolling 8,138 adults with type 2 diabetes across 2015-2017.

SUSTAIN-1 (Sorli et al., Diabetes Care 2017): Semaglutide monotherapy vs placebo. 30-week trial. A1C reduction: 1.5% at 0.5 mg dose, 1.6% at 1 mg dose, vs 0.1% placebo. Weight loss: 3.5 kg at 0.5 mg, 4.5 kg at 1 mg.

SUSTAIN-2 (Ahrén et al., Lancet Diabetes & Endocrinology 2017): Semaglutide vs sitagliptin (a DPP-4 inhibitor). 56-week trial. A1C reduction: 1.3% at 1 mg semaglutide vs 0.5% sitagliptin. Weight loss: 4.3 kg vs 0.9 kg.

SUSTAIN-3 (Ahmann et al., Diabetes Care 2018): Semaglutide vs exenatide extended-release (another GLP-1 agonist). 56-week trial. A1C reduction: 1.5% semaglutide vs 0.9% exenatide. Weight loss: 5.6 kg vs 1.9 kg.

SUSTAIN-6 (Marso et al., New England Journal of Medicine 2016): Cardiovascular outcomes trial. 104-week trial. Primary outcome: 26% reduction in major adverse cardiovascular events (MACE) with semaglutide vs placebo. This trial was published before the FDA approval and became the basis for the 2020 cardiovascular indication.

The FDA's approval review noted three safety concerns that required label warnings:

1. Thyroid C-cell tumors: Semaglutide caused thyroid C-cell tumors in rodent studies. The label includes a boxed warning contraindicating use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

1. Pancreatitis risk: 0.3% of semaglutide patients developed acute pancreatitis vs 0.1% placebo in pooled trials. The label warns against use in patients with a history of pancreatitis.

1. Diabetic retinopathy complications: SUSTAIN-6 showed a 76% increase in retinopathy complications in the semaglutide group, attributed to rapid A1C reduction in patients with pre-existing retinopathy. The label warns about monitoring patients with diabetic retinopathy.

The approval was standard (not accelerated), meaning Novo Nordisk provided complete efficacy and safety data. No post-marketing requirements were imposed beyond routine pharmacovigilance.

Timeline of label expansions (2017 to 2026)

Date	Label change	Basis
December 5, 2017	Initial approval: 0.5 mg and 1 mg doses for type 2 diabetes	SUSTAIN 1-5 trials
January 24, 2020	Cardiovascular indication added: "reduce risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease"	SUSTAIN-6 trial
January 28, 2022	2 mg dose approved, doubling maximum dose	SUSTAIN FORTE trial (Frías et al., JAMA 2021)
June 4, 2021	Wegovy (same molecule, higher dose) approved for chronic weight management	STEP 1-4 trials (separate NDA)
March 2023	Label updated with additional cardiovascular data from SELECT trial (published late 2023)	SELECT trial showing benefit in patients without diabetes
October 2025	Prescribing information updated to include shortage-related compounding guidance	FDA shortage list status
April 2026	Current approved indications remain unchanged; no weight-loss indication added to Ozempic label	N/A

The pattern across these updates: each label expansion required a completed Phase 3 trial and a supplemental NDA submission. The FDA does not add indications based on real-world evidence or off-label use patterns, only on prospective randomized controlled trials.

What most articles get wrong about Ozempic's approval

Misconception 1: "Ozempic was approved for weight loss in 2017."

False. The December 2017 approval was exclusively for type 2 diabetes management. Weight loss was documented as a secondary outcome in the SUSTAIN trials, but the FDA did not approve weight loss as an indication. Ozempic's label has never included obesity or weight management as an approved use.

The confusion stems from the fact that the same molecule (semaglutide) was later approved under a different brand name (Wegovy) for weight loss in June 2021. Wegovy uses higher doses (up to 2.4 mg weekly) and required separate clinical trials (the STEP program) focused on weight loss in patients without diabetes.

Misconception 2: "The 2 mg dose was part of the original approval."

False. The original December 2017 approval covered only 0.5 mg and 1 mg doses. The 2 mg dose was approved on January 28, 2022, based on the SUSTAIN FORTE trial. This trial showed that patients who didn't reach A1C targets on 1 mg could achieve an additional 0.4% A1C reduction by escalating to 2 mg (Frías et al., JAMA 2021).

Many articles conflate the 2 mg Ozempic dose with the 2.4 mg Wegovy dose. These are different products with different approval dates and different indications.

Misconception 3: "Ozempic's cardiovascular benefit was known at approval."

Partially true. The SUSTAIN-6 cardiovascular outcomes trial was published in September 2016, before the December 2017 approval. However, the cardiovascular risk reduction was not added to the Ozempic label until January 2020. The FDA required additional data analysis and a formal supplemental application before allowing cardiovascular claims on the label.

Between December 2017 and January 2020, providers knew about the SUSTAIN-6 results, but Novo Nordisk could not market Ozempic as reducing cardiovascular risk. This is a common pattern: trial results are published before the FDA updates the label to reflect them.

The cardiovascular indication: how SUSTAIN-6 changed the label

On January 24, 2020, the FDA approved a label update adding cardiovascular risk reduction to Ozempic's approved indications. The updated label states: "Ozempic is indicated to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and established cardiovascular disease."

This change was based on SUSTAIN-6, a cardiovascular outcomes trial that enrolled 3,297 patients with type 2 diabetes and high cardiovascular risk. The trial ran for 104 weeks (two years) and measured a composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Results (Marso et al., NEJM 2016):

• MACE occurred in 6.6% of semaglutide patients vs 8.9% of placebo patients
• Hazard ratio: 0.74 (95% CI 0.58-0.95), representing a 26% relative risk reduction
• The benefit was driven primarily by reductions in non-fatal stroke (39% reduction) and non-fatal MI (26% reduction)
• No significant reduction in cardiovascular death alone

The cardiovascular indication matters for three reasons:

Reason 1: Insurance coverage. Many Medicare Part D and commercial plans cover GLP-1 agonists more readily when the patient has both diabetes and established cardiovascular disease. The cardiovascular indication strengthens the prior authorization case.

Reason 2: Clinical decision-making. For patients with type 2 diabetes and a history of heart attack, stroke, or coronary artery disease, Ozempic becomes a preferred agent over GLP-1 drugs without cardiovascular outcome data (like Trulicity before 2019).

Reason 3: Competitive positioning. The cardiovascular indication differentiated Ozempic from earlier GLP-1 drugs. Victoza (liraglutide) had a cardiovascular indication since 2017, but required daily injections. Ozempic offered once-weekly dosing with similar cardiovascular benefit.

The SELECT trial, published in late 2023, extended the cardiovascular evidence to patients without diabetes (Lincoff et al., NEJM 2023). However, this trial used 2.4 mg semaglutide (the Wegovy dose), not Ozempic doses. As of April 2026, the FDA has not added a cardiovascular indication to Wegovy's label, though the data supports it.

The 2 mg dose approval and why it took until 2022

The FDA approved the 2 mg Ozempic dose on January 28, 2022, more than four years after the initial approval. The delay reflects the FDA's requirement for dose-specific trial data.

The approval was based on SUSTAIN FORTE, a 40-week trial comparing 2 mg semaglutide vs 1 mg semaglutide in 961 adults with type 2 diabetes who had not reached A1C targets on 1 mg (Frías et al., JAMA 2021).

Results:

• A1C reduction from baseline: 2.2% at 2 mg vs 1.9% at 1 mg (additional 0.3% benefit)
• Percentage of patients reaching A1C below 7%: 80% at 2 mg vs 68% at 1 mg
• Weight loss: 6.9 kg at 2 mg vs 6.0 kg at 1 mg (additional 0.9 kg)
• Adverse events: nausea occurred in 20% of 2 mg patients vs 12% of 1 mg patients

The trial design addressed a specific clinical question: what should providers do when a patient on 1 mg Ozempic doesn't reach their A1C goal? The answer: escalate to 2 mg rather than switch to a different medication.

Why the delay until 2022?

Novo Nordisk prioritized the Wegovy approval (June 2021) over the Ozempic 2 mg dose. The STEP trials for Wegovy used 2.4 mg semaglutide, a dose higher than any Ozempic dose. Novo Nordisk conducted SUSTAIN FORTE in parallel but submitted the supplemental NDA for the 2 mg Ozempic dose after the Wegovy NDA.

The 2 mg dose also required manufacturing changes. The original Ozempic pens delivered 0.5 mg or 1 mg per injection. The 2 mg dose required a new pen design with higher concentration solution. The FDA's approval included review of the new pen's mechanical reliability and dose accuracy.

As of April 2026, the 2 mg dose represents the maximum approved Ozempic dose. Some patients and providers ask about higher doses (matching Wegovy's 2.4 mg), but the Ozempic label does not permit doses above 2 mg. Prescribing 2.4 mg Ozempic would be off-label and not supported by the approved prescribing information.

Ozempic vs Wegovy: why two approval dates for the same molecule

Semaglutide is one molecule with two brand names, two approval dates, and two distinct indications:

Brand	Approval date	Approved indication	Doses	NDA number
Ozempic	December 5, 2017	Type 2 diabetes (glycemic control and cardiovascular risk reduction)	0.5 mg, 1 mg, 2 mg weekly	209637
Wegovy	June 4, 2021	Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity	2.4 mg weekly	215256

Why two separate approvals?

The FDA requires separate NDAs for different indications, even when the active ingredient is identical. Ozempic's approval was based on the SUSTAIN trials, which enrolled patients with type 2 diabetes and measured A1C reduction as the primary outcome. Wegovy's approval was based on the STEP trials, which enrolled patients with obesity (with or without diabetes) and measured weight loss as the primary outcome.

The STEP trials (Wilding et al., NEJM 2021; Davies et al., Lancet 2021) used a 2.4 mg weekly dose, higher than any Ozempic dose at the time. The trials showed 15% to 17% total body weight loss over 68 weeks in patients without diabetes, far exceeding the weight loss seen in the SUSTAIN trials.

Can you use Ozempic for weight loss?

Legally, yes (off-label prescribing is permitted). Practically, insurance won't cover it. Most commercial and Medicare Part D plans deny coverage for Ozempic prescribed for weight loss because the FDA-approved indication is diabetes only. They will cover Wegovy for weight loss (if the plan includes obesity medications), but Wegovy has been on shortage intermittently since 2021.

This creates the pattern we see in FormBlends consultations: patients with type 2 diabetes and obesity get Ozempic covered. Patients with obesity but no diabetes get Wegovy denied or face $1,300+ monthly cash prices. Compounded semaglutide becomes the accessible alternative for the latter group.

The 2023-2026 shortage and FDA regulatory response

Ozempic appeared on the FDA drug shortage list in March 2023 and remained there through Q1 2026 with intermittent availability. The shortage was driven by demand exceeding manufacturing capacity, not by a manufacturing defect or safety issue.

Timeline of shortage:

• March 2023: All Ozempic doses (0.5 mg, 1 mg, 2 mg) listed as "currently in shortage" on FDA shortage database
• June 2023: 0.5 mg and 1 mg doses removed from shortage list; 2 mg remains in shortage
• September 2023: All doses back on shortage list
• January 2024: Novo Nordisk announces manufacturing capacity expansion; intermittent availability continues
• April 2024: FDA issues guidance on compounding semaglutide during shortage
• October 2025: Shortage status continues; FDA updates compounding guidance
• April 2026: Ozempic remains on shortage list with "available" status for 0.5 mg and 1 mg, "limited availability" for 2 mg

Regulatory impact:

The FDA's drug shortage regulations (Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act) permit compounding pharmacies to prepare copies of commercially available drugs when those drugs are on the FDA shortage list. This created the legal pathway for compounded semaglutide.

Between 2023 and 2026, hundreds of compounding pharmacies began producing semaglutide, and telehealth platforms (including FormBlends) connected patients to prescribers and compounding pharmacies. The FDA issued guidance in April 2024 clarifying that compounded semaglutide must:

1. Be prepared in response to a patient-specific prescription (not bulk manufacturing)
2. Match the approved salt form (semaglutide base, not semaglutide sodium)
3. Include appropriate beyond-use dating based on stability studies
4. Not make therapeutic equivalence claims to Ozempic or Wegovy

The shortage also triggered a proliferation of unregulated "semaglutide" products sold online without prescriptions. The FDA issued 14 warning letters between March 2023 and December 2025 to companies selling semaglutide without valid prescriptions or from non-licensed facilities.

As of April 2026, the shortage persists, but availability has improved. Patients with commercial insurance and prior authorization approvals can usually fill Ozempic prescriptions within one to two weeks. Patients without insurance or with plan denials face longer waits or turn to compounded alternatives.

Current approved indications as of April 2026

As of April 2026, Ozempic's FDA-approved indications remain:

Indication 1: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Indication 2: To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Not approved for:

• Weight loss or obesity management (use Wegovy for this indication)
• Type 1 diabetes
• Diabetic ketoacidosis
• Patients under 18 years old
• Prevention of cardiovascular disease in patients without established disease

Dosing as of April 2026:

• Starting dose: 0.25 mg once weekly for 4 weeks (not a therapeutic dose, for tolerability only)
• Maintenance doses: 0.5 mg, 1 mg, or 2 mg once weekly
• Escalation: increase dose every 4 weeks if additional glycemic control needed and tolerability permits
• Maximum dose: 2 mg once weekly

The prescribing information has not changed substantively since the January 2022 addition of the 2 mg dose. Novo Nordisk submitted post-marketing data from the SELECT trial (cardiovascular outcomes in patients without diabetes), but the FDA has not added new indications to the Ozempic label based on this data.

How approval dates affect insurance coverage and compounding legality

Insurance coverage:

Most insurance plans, including Medicare Part D, cover only FDA-approved indications. For Ozempic, this means:

• Covered: Prescriptions written for type 2 diabetes management, with diagnosis code E11.x (type 2 diabetes) on the prescription
• Not covered: Prescriptions written for weight loss, obesity, or "off-label use," even if the patient has obesity

This creates a coverage gap. A patient with BMI 38 and no diabetes cannot get Ozempic covered, even though the medication would likely produce substantial weight loss. The same patient could get Wegovy covered if their plan includes obesity medications, but fewer than 30% of commercial plans covered Wegovy as of 2025 (KFF analysis).

Prior authorization requirements are tied to the approval date and indication. Most plans require PA for Ozempic, asking for:

• Confirmed type 2 diabetes diagnosis (A1C ≥6.5% or fasting glucose ≥126 mg/dL)
• Trial and failure of metformin (unless contraindicated)
• BMI documentation (some plans require BMI ≥27)

Compounding legality:

The FDA permits compounding of drugs on the shortage list under Section 503A (patient-specific compounding by traditional pharmacies) and Section 503B (outsourcing facilities producing larger batches). The approval date matters because:

1. Compounders can only copy the approved salt form and route of administration. Ozempic is semaglutide base, subcutaneous injection. Compounders cannot legally produce oral semaglutide (that's Rybelsus, a separate NDA) or semaglutide sodium (different salt form).

1. Once Ozempic is removed from the FDA shortage list, compounding becomes illegal under Section 503A unless the compounder can demonstrate the prescription requires a modification not commercially available (different dose, different preservative for allergy, etc.).

As of April 2026, Ozempic remains on the shortage list, so compounding continues legally. If Novo Nordisk resolves the shortage and the FDA removes Ozempic from the list, most telehealth compounded semaglutide programs would need to shut down or pivot to a different molecule.

What's next: pending label changes and post-market studies

Pending label changes (as of April 2026):

Novo Nordisk has not announced plans to seek additional indications for Ozempic. The company's strategy appears to be maintaining Ozempic as the diabetes brand and Wegovy as the weight-loss brand, even though the molecule is identical.

One possible future change: adding a cardiovascular indication to Wegovy based on the SELECT trial. SELECT showed a 20% reduction in MACE in patients with obesity and cardiovascular disease but without diabetes (Lincoff et al., NEJM 2023). If the FDA adds this indication to Wegovy, it would make Wegovy the first obesity medication with a cardiovascular benefit claim.

Post-market studies required by FDA:

The FDA did not impose post-marketing requirements (PMRs) at the time of Ozempic's approval. However, Novo Nordisk is conducting several ongoing studies:

1. Pediatric studies: Evaluating semaglutide in adolescents (ages 10-17) with type 2 diabetes. If positive, could lead to pediatric approval.

1. SOUL trial: Cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease. Results expected 2027.

1. Long-term safety registry: Monitoring thyroid cancer incidence in patients exposed to semaglutide for 5+ years. This is a voluntary post-market commitment, not an FDA requirement.

Potential future dose increases:

Novo Nordisk has investigated doses above 2.4 mg in research settings but has not announced plans to seek approval for higher doses. The dose-response curve for A1C reduction appears to plateau around 1-2 mg, and higher doses increase nausea and vomiting without proportional glycemic benefit.

The FormBlends clinical pattern: what approval dates reveal about patient access

Across 18 months of FormBlends consultations (mid-2024 through early 2026), we see a consistent pattern tied directly to approval dates and indications:

Pattern 1: The diagnosis determines the door.

Patients with documented type 2 diabetes (A1C ≥6.5%) get insurance coverage for Ozempic approximately 60% of the time after prior authorization. Patients without diabetes but with obesity get coverage approximately 5% of the time, almost always requiring an appeal and peer-to-peer review.

The December 2017 approval date locked in "type 2 diabetes" as the gatekeeper diagnosis. Every insurance medical policy we review references the FDA-approved indication verbatim. Off-label use for weight loss is acknowledged but not covered.

Pattern 2: The 2 mg dose is the most denied.

Even among patients with diabetes, the 2 mg dose faces higher denial rates than 0.5 mg or 1 mg. Insurance medical directors interpret the January 2022 approval date as evidence that 2 mg is "not first-line." Plans require documentation of inadequate response to 1 mg before approving 2 mg, mirroring the SUSTAIN FORTE trial design.

This creates a coverage ladder: patients start at 0.5 mg, escalate to 1 mg after 12-16 weeks, then request 2 mg only if A1C remains above target. Each step requires new prior authorization.

Pattern 3: Compounded semaglutide fills the weight-loss gap.

Roughly 70% of FormBlends semaglutide consultations involve patients without type 2 diabetes seeking weight loss. These patients cannot access Ozempic through insurance. Wegovy is either not covered or priced at $1,300+ monthly. Compounded semaglutide at $179 to $279 monthly becomes the only accessible option.

The approval date matters here because it defines what's legal to compound. We can compound semaglutide base (the Ozempic molecule) but not tirzepatide (Mounjaro/Zepbound) when tirzepatide is not on the FDA shortage list. The regulatory distinction is binary: on shortage list = compoundable; off shortage list = not compoundable (with narrow exceptions).

This pattern will shift dramatically if the FDA removes Ozempic from the shortage list in 2026 or 2027. The entire telehealth compounded semaglutide industry is contingent on the continuation of the shortage designation.

FAQ

When did Ozempic get FDA approval? Ozempic was approved by the FDA on December 5, 2017, for the treatment of type 2 diabetes in adults. The approval covered 0.5 mg and 1 mg once-weekly doses. The 2 mg dose was added in January 2022.

Is Ozempic approved for weight loss? No. Ozempic is approved only for type 2 diabetes management and cardiovascular risk reduction in patients with diabetes and established heart disease. The same molecule (semaglutide) is approved for weight loss under the brand name Wegovy, which was approved in June 2021.

What trials led to Ozempic's approval? The FDA based approval on the SUSTAIN clinical trial program, which included eight Phase 3 trials enrolling over 8,000 patients with type 2 diabetes. Key trials included SUSTAIN-1 (monotherapy), SUSTAIN-2 (vs sitagliptin), SUSTAIN-3 (vs exenatide), and SUSTAIN-6 (cardiovascular outcomes).

When was the cardiovascular indication added to Ozempic? The cardiovascular risk reduction indication was added to the Ozempic label on January 24, 2020, based on the SUSTAIN-6 trial showing a 26% reduction in major adverse cardiovascular events compared to placebo.

Why did the 2 mg dose approval take until 2022? The 2 mg dose required a separate clinical trial (SUSTAIN FORTE) demonstrating additional benefit over the 1 mg dose. Novo Nordisk submitted the supplemental NDA in 2021, and the FDA approved it on January 28, 2022. The delay also involved manufacturing changes to produce higher-concentration pens.

Can doctors prescribe Ozempic off-label for weight loss? Yes. Off-label prescribing is legal and common. However, most insurance plans will not cover Ozempic for weight loss because it's not an FDA-approved indication. Patients typically pay cash prices ($940 to $1,150 per month) or use compounded semaglutide alternatives.

What's the difference between Ozempic and Wegovy approval dates? Ozempic was approved December 5, 2017, for type 2 diabetes. Wegovy was approved June 4, 2021, for chronic weight management. They contain the same active ingredient (semaglutide) but required separate clinical trial programs and separate FDA applications because the indications are different.

Is Ozempic still on the FDA shortage list in 2026? Yes, as of April 2026. Ozempic has been on the FDA drug shortage list intermittently since March 2023. The 0.5 mg and 1 mg doses are currently listed as "available," while the 2 mg dose has "limited availability." This shortage status permits legal compounding of semaglutide.

Does Medicare cover Ozempic? Medicare Part D plans cover Ozempic for type 2 diabetes management (an FDA-approved indication). Coverage typically requires prior authorization and diagnosis documentation. Medicare does not cover Ozempic for weight loss. Copays range from $200 to $500 monthly depending on the plan.

What happens if Ozempic is removed from the shortage list? If the FDA removes Ozempic from the shortage list, compounding pharmacies can no longer legally produce semaglutide copies under Section 503A regulations (except in narrow circumstances requiring customization). This would eliminate most telehealth compounded semaglutide programs unless they pivot to a different shortage-listed medication.

Are there any pediatric approvals for Ozempic? No. As of April 2026, Ozempic is approved only for adults (18 years and older). Novo Nordisk is conducting trials in adolescents with type 2 diabetes, but no pediatric indication has been approved yet.

What is the maximum approved Ozempic dose? The maximum approved dose is 2 mg once weekly, approved in January 2022. Doses higher than 2 mg are not approved for Ozempic. Wegovy (the weight-loss formulation) goes up to 2.4 mg weekly, but that's a separate product with a separate approval.

Sources

1. FDA. Ozempic (semaglutide) injection approval letter, NDA 209637. December 5, 2017.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetes Care. 2017;40(9):1193-1201.
3. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin in patients with type 2 diabetes (SUSTAIN 2). Lancet Diabetes Endocrinol. 2017;5(5):341-354.
4. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Care. 2018;41(2):258-266.
5. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.
6. Frías JP et al. Efficacy and safety of dulaglutide after 104 weeks in type 2 diabetes (AWARD-11). Diabetes Obes Metab. 2021;23(3):674-683.
7. FDA. Ozempic label update: cardiovascular indication. January 24, 2020.
8. Frías JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE). JAMA. 2021;326(15):1489-1497.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
11. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
12. FDA Drug Shortage Database. Semaglutide injection. Accessed April 2026.
13. FDA. Compounding and the FDA: Questions and Answers (updated guidance on semaglutide compounding). April 2024.
14. Kaiser Family Foundation. Employer health benefits survey: coverage of GLP-1 medications for obesity. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.